Daily Probiotic Support features concentrated probiotic factors that are ideal for patients to support a healthy balance of intestinal microflora and healthy intestinal function.
Daily Probiotic Support provides a full 60 day supply of the optimal quantity, 15 billion friendly probiotics per capsule.
♦ These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any diseases.
Product Info
Probiotics are beneficial microorganisms that live in our digestive tracts. When present in sufficient numbers, they are known to confer important life-enhancing effects, in exchange for a small portion of our food. Just as we metabolize food and constantly produce various substances in the course of our lives such as sweat, carbon dioxide, saliva and tear fluid, these organisms, as they go about their lives, continually release substances that support our bodies. These substances generally are not found in significant amounts in the food that we eat, but rather are produced by these helpful creatures as they act on our food; some of the substances that they produce enhance the absorption of nutrients that are already present in the food.
Two extensively documented types of probiotics are Lactobacilli and Bifidobacteria. These include Lactobacillus acidophilus NCFM (L. acidophilus) and Bifidobacteria Lactis Bi-07 (B. lactis), which were selected for Daily Probiotic Support because of their outstanding resistance to the necessary but highly caustic fluids (hydrochloric acid and bile) in the digestive tract and their ability to effectively implant themselves and reproduce along the intestinal wall.
L. acidophilus and B. lactis tend to reside in the small and large intestines respectively. Both types are known for abundant production of lactic acid, which is responsible for much of the sour flavor of yogurt. The sustained presence of generous amounts this lactic acid in the intestines creates an environment that is highly unfavorable to many of the harmful microorganisms (pathogens) that are also naturally present there. Acetic acid, which gives vinegar its sharpness, is concurrently produced, and is similar in effect. In addition to these two acids, these bacteria produce an array of other compounds that specifically limit the survival of unfriendly bacteria and yeast. As more probiotics populate the intestines, less pathogens are able to live there. Conversely, as pathogens are edged out, probiotics become freer to thrive and confer their other benefits.
Besides inhibiting pathogens, Lactobacilli and Bifidobacteria produce butyric acid, which directly nourishes the cells of the colon with their highly preferred food, strengthens the intestinal mucous membrane, and increases local blood circulation. Another substance that is produced, propionic acid, has been shown to regulate blood cholesterol. A related but independent fact is that L. acidophilus NCFM directly feeds on cholesterol as part of its growth and reproductive processes, further regulating the availability of excess dietary cholesterol.
MD Info
RESEARCH:
Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA. camilleri.michael@mayo.edu
The irritable bowel syndrome (IBS) follows an acute, presumably infectious diarrheal illness in approximately 15% of patients. There may be a persistent, mild inflammatory state with changes in mucosal function or structure. Changes in the colonic bacterial flora reported in IBS seem related to predominant bowel. Colonic bacteria normally metabolize nutrients with the formation of gas and short chain fatty acids. The latter may induce propulsive contractions and accelerate colonic transit or they may enhance fluid and sodium absorption in the colon. This review addresses the mechanisms, rationale and current evidence for the efficacy of probiotics, including Lactobacilli, Bifidobacteria, and VSL#3, in the treatment of IBS. The mechanisms influenced by probiotics include immune function, motility, and the intraluminal milieu. Probiotics may suppress the low-grade inflammation associated with IBS or restore normal local immune function. Lactobacilli and Bifidobacteria subspecies are able to deconjugate and absorb bile acids, potentially reducing the colonic mucosal secretion of mucin and fluids that may contribute to functional diarrhea or IBS with diarrhea. Therapeutic trials show the potential benefit of Bifidobacteria or Lactobacilli species alone or in the specific probiotic combination, VSL#3, on symptoms in IBS. Colonic transit was retarded in IBS patients treated with VSL#3 without induction of significant changes in bowel function. In summary, probiotics are promising therapies in IBS.
MORE ARTICLES...
1. Oral probiotics prevent necrotizing enterocolitis .
The Journal of Pediatrics , Volume 148 , Issue 6 , Pages 849 - 849
H . Lin , B . Su , W . Oh
SCIENITIFIC PAPERS: Alimentary Pharmabiotic Centre, National University of Ireland, Cork, Ireland. e.quigley@ucc.ie
The clear delineation of a postinfective variety of irritable bowel syndrome (IBS), and the description, in a number of studies, of evidence of low-grade inflammation and immune activation in IBS, suggest a role for a dysfunctional relationship between the indigenous flora and the host in IBS and, accordingly, provide a clear rationale for the use of probiotics in this disorder. Other modes of action, including bacterial displacement and alterations in luminal contents, are also plausible. Although clinical evidence of efficacy is now beginning to emerge, a review of available trials emphasizes the importance of clear definition of strain selection, dose, and viability. The possible roles of cotherapy or sequential therapy with antibiotics, probiotics, prokinetics, or other agents, also deserve further study. The role of the enteric flora is evidently an area of great potential in IBS; we are on the threshold of a new era of research and therapy for this common disorder.
AIM100 Nutrition takes care of strain selection, dose and viability for you.
ANOTHER INTERESTING ARTICLE ON PROBIOTICS
Department of Medicine, University of Manchester, Manchester, UK.
BACKGROUND: Probiotic bacteria exhibit a variety of properties, including immunomodulatory activity, which are unique to a particular strain. Thus, not all species will necessarily have the same therapeutic potential in a particular condition. We have preliminary evidence that Bifidobacterium infantis 35624 may have utility in irritable bowel syndrome (IBS). OBJECTIVES: This study was designed to confirm the efficacy of the probiotic bacteria B. infantis 35624 in a large-scale, multicenter, clinical trial of women with IBS. A second objective of the study was to determine the optimal dosage of probiotic for administration in an encapsulated formulation. METHODS: After a 2-wk baseline, 362 primary care IBS patients, with any bowel habit subtype, were randomized to either placebo or freeze-dried, encapsulated B. infantis at a dose of 1 x 10(6), 1 x 10(8), or 1 x 10(10), cfu/mL for 4 wk. IBS symptoms were monitored daily and scored on to a 6-point Likert scale with the primary outcome variable being abdominal pain or discomfort. A composite symptom score, the subject's global assessment of IBS symptom relief, and measures of quality of life (using the IBS-QOL instrument) were also recorded. RESULTS: B. infantis 35624 at a dose of 1 x 10(8) cfu was significantly superior to placebo and all other bifidobacterium doses for the primary efficacy variable of abdominal pain as well as the composite score and scores for bloating, bowel dysfunction, incomplete evacuation, straining, and the passage of gas at the end of the 4-wk study. The improvement in global symptom assessment exceeded placebo by more than 20% (p < 0.02). Two other doses of probiotic (1 x 10(6) and 1 x 10(10)) were not significantly different from placebo; of these, the 1 x 10(10) dose was associated with significant formulation problems. No significant adverse events were recorded. CONCLUSIONS: B. infantis 35624 is a probiotic that specifically relieves many of the symptoms of IBS. At a dosage level of 1 x 10(8) cfu, it can be delivered by a capsule making it stable, convenient to administer, and amenable to widespread use. The lack of benefits observed with the other dosage levels of the probiotic highlight the need for clinical data in the final dosage form and dose of probiotic before these products should be used in practice.
PMID: 16863564 [PubMed - indexed for MEDLINE]
Label
Suggested usage: Take 1 capsule daily or as directed by your healthcare physician.
Each capsule contains:
A 50:50 blend of 15 billion friendly probiotics:
Lactobacillus Acidophillus NCFM strain
Bifidobacterium Lactis B1-107 ( B.Infantis )
Globulin protein concentrate 170 mg
* Bifidobacteria and Lactobacilli probiotic strains consume soy- and milk-derived nutrients as a food source during one step of the fermentation process. No additional soy- or milk-derived nutrients were added outside of this fermentation step.
Caution: This product may not be suitable for individuals with severe milk or soy allergies.
Formulated to exclude: Nuts, tree nuts, fish, crustacean shellfish, or artificial colors, sweeteners, or preservatives.
Notice: For maximum stability and vitality, keep refrigerated
